Bristol-Myers Squibb
BMY
$68.20
Share price
0.19%
Change (1 day)
-6.72%
Change (1 year)
Categories
Operating Margin for Bristol-Myers Squibb (BMY)
Operating Margin as of March 2023 (TTM): 16.70%
According to Bristol-Myers Squibb's latest financial reports and stock price the company's current Operating Margin is 16.70%. At the end of 2021 the company had an Operating Margin of 17.46%.
Operating Margin history for Bristol-Myers Squibb from 2001 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | 17.46% | -208.03% |
| 2020 | -16.16% | -184.93% |
| 2019 | 19.03% | -28.07% |
| 2018 | 26.45% | 7.11% |
| 2017 | 24.70% | -18.89% |
| 2016 | 30.45% | 142.76% |
| 2015 | 12.54% | -16.36% |
| 2014 | 14.99% | -15.02% |
| 2013 | 17.64% | 32.87% |
| 2012 | 13.28% | -59.59% |
| 2011 | 32.86% | 5.46% |
| 2010 | 31.16% | 4.61% |
| 2009 | 29.79% | 12.13% |
| 2008 | 26.56% | 45.42% |
| 2007 | 18.27% | 24.18% |
| 2006 | 14.71% | -37.44% |
| 2005 | 23.51% | 3.14% |
| 2004 | 22.80% | 1.47% |
| 2003 | 22.47% | 53.78% |
| 2002 | 14.61% | -2.02% |
| 2001 | 14.91% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 24.28% | 45.39% | 🇺🇸 USA |
 Novartis NVS | 16.15% | -3.29% | 🇨🇭 Switzerland |
 Pfizer PFE | 29.90% | 79.04% | 🇺🇸 USA |
 AbbVie ABBV | 23.21% | 38.98% | 🇺🇸 USA |
 Eli Lilly LLY | 23.84% | 42.75% | 🇺🇸 USA |
 Amgen AMGN | 27.90% | 67.07% | 🇺🇸 USA |
 Sanofi SNY | 19.90% | 19.16% | 🇫🇷 France |
 Biogen BIIB | 35.30% | 111.38% | 🇺🇸 USA |
 Merck MRK | 28.49% | 70.60% | 🇺🇸 USA |
 AstraZeneca AZN | -0.70% | -104.19% | 🇬🇧 UK |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.